Clinical usefulness of anti-neutrophil cytoplasmic antibodies in childhood systemic lupus erythematosus

被引:0
作者
Cardinalli, Antonio [1 ]
Ginaca, Alejandra [2 ]
Espada, Graciela [3 ]
Cristina Pizzimenti, Maria [1 ]
Emilia Rivas, Maria [2 ]
Leggire, Lina [3 ]
Griemberg, Gloria [1 ]
机构
[1] UBA, Fac Farm & Bioquim, Lab Inmunol Clin, Dept Bioquim Clin,Hosp Clin Jose de San Martin, Buenos Aires, DF, Argentina
[2] Hosp Ninos Dr Ricardo Gutierrez, Lab Inmunol, Buenos Aires, DF, Argentina
[3] Hosp Ninos Dr Ricardo Gutierrez, Serv Reumatol, Buenos Aires, DF, Argentina
来源
ACTA BIOQUIMICA CLINICA LATINOAMERICANA | 2013年 / 47卷 / 01期
关键词
antineutrophil cytoplasmic autoantibodies; childhood systemic lupus erythematosus; sorbent antinuclear antibody; INDIRECT IMMUNOFLUORESCENCE; ANCA ASSAYS; AUTOANTIBODIES; MYELOPEROXIDASE; VASCULITIS; STANDARDIZATION; GRANULOMATOSIS; SPECIFICITY; DIAGNOSIS; DISEASES;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Not so many studies evaluating the prevalence and the clinical usefulness of ANCA in childhood systemic lupus erythematosus (SLE) have been published. Furthermore, the interference of antinuclear antibodies (ANA) with ANCA detection has been described. This study was designed to detect ANCA prevalence in children with SLE, avoiding ANA interference. In order to differentiate certain groups displaying vasculitis or glomerulonefritis, the antigenic specificity of ANCA and their association with the disease activity. Different clinical features were also assessed. A total of 51 patients (mean age, 14.6 years) were studied. SLE was established following the American College of Rheumatology criteria. Patients were clustered according to the Disease Activity Index (SLE-DAI). ANCA were detected by indirect immunofluorescence (IFI). Antigenic specificity was characterized by a lineal qualitative home-made immunoassay (LIA-Blot). Interference by ANA and native anti-DNA antibodies (aDNAn) was avoided by specific sorbents. Prevalence of pANCA and aANCA was 9.8% (5/51) and 5.9% (3/51), respectively. Anti-myeloperoxidase (aMPO) and anti-lactoferrin (aLf) frequencies were 9.8% (5/51) and 13.7% (7/51), respectively. No cANCA, anti-proteinase 3 or anti-elastase antibodies were detected. Both pANCA and aMPO, alone or associated, proved to be related to the presence of glomerulonephritis (p=0.02, chi square), but not to the SLE-DAI. This study asserts the presence of ANCA in children with SLE. In addition, a significant association of pANCA and anti-MPO with glomerulonephritis was found. Further studies including larger number of patients are needed to assess the association of ANCA with other clinical features.
引用
收藏
页码:145 / 153
页数:9
相关论文
共 26 条
[1]  
CAMBRIDGE G, 1994, BRIT J RHEUMATOL, V33, P109
[2]  
Cardinalli A, 1994, ACTA BIOQUIM CLIN L, V4, P561
[3]  
Cardinalli A, 1997, INMUNOLOGIA, P1
[4]   DETERMINATION OF ANTINEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) SPECIFICITY BY IMMUNOFLUORESCENCE ON CHRONIC MYELOCYTIC-LEUKEMIA CELLS [J].
CHEVAILLER, A ;
NOEL, LH ;
RENIER, G ;
GARDEMBASPAIN, M ;
SUBRA, JF ;
NUSBAUM, P ;
HUREZ, D ;
LESAVRE, P .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 147 (01) :101-109
[5]   ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODIES WITH SPECIFICITY FOR MYELOPEROXIDASE IN PATIENTS WITH SYSTEMIC VASCULITIS AND IDIOPATHIC NECROTIZING AND CRESCENTIC GLOMERULONEPHRITIS [J].
FALK, RJ ;
JENNETTE, JC .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (25) :1651-1657
[6]  
GROSS WL, 1993, CLIN EXP IMMUNOL, V91, P1
[7]   Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA) - A report on the second phase of an international cooperative study on the standardization of ANCA assays [J].
Hagen, EC ;
Andrassy, K ;
Csernok, E ;
Daha, MR ;
Gaskin, G ;
Gross, WL ;
Hansen, B ;
Heigl, Z ;
Hermans, J ;
Jayne, D ;
Kallenberg, CGM ;
Lesavre, P ;
Lockwood, CM ;
Ludemann, J ;
MascartLemone, F ;
Mirapeix, E ;
Pusey, CD ;
Rasmussen, N ;
Sinico, RA ;
Tzioufas, A ;
Wieslander, J ;
Wiik, A ;
VanderWoude, FJ .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 196 (01) :1-15
[8]  
HAGEN EC, 1993, J IMMUNOL METHODS, V159, P1
[9]  
Hagen EC, 1996, BLOOD, V81, P226
[10]  
LEE SS, 1992, BRIT J RHEUMATOL, V31, P669